Skip to content

Exploring the Effect of Soy Protein Plant-Based Diets on Improving Chronic Low-Grade Inflammation in CKD Based on Gut Microbiota Regulation

Exploring the Effect of Soy Protein Plant-Based Diets on Improving Chronic Low-Grade Inflammation in CKD Based on Gut Microbiota Regulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120590
Enrollment
Unknown
Registered
2026-03-17
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Control group:Administer an animal protein-dominated dietary regimen
Intervention group:Administer a soy protein-dominated, plant-based, anti-inflammatory dietary regimen

Sponsors

Hangzhou Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with CKD stages 3-4 (15 mL/min/1.73 m^2 <= eGFR <= 60 mL/min/1.73 m^2); 2.Aged 18-75 years, regardless of gender; 3.Patients with normal comprehension and reading ability; 4.Patients who voluntarily participate in the study and provide signed informed consent;

Exclusion criteria

Exclusion criteria: 1.Patients with other serious comorbidities, such as malignant tumors, severe liver dysfunction (ALT or AST > 2.5 × ULN), gastrointestinal bleeding, severe primary hematopoietic system diseases; severe hypertension (systolic BP >= 200 mmHg or diastolic BP >= 120 mmHg) that is difficult to control; severe malnutrition (SGA score of C); or severe hypoproteinemia (albumin < 30 g/L); 2.History of acute cardiovascular or cerebrovascular events within the last 6 months, such as myocardial infarction, heart failure, unstable angina, transient ischemic attack, or stroke; 3.History of systemic infectious diseases within the last month; 4.Patients expected to require dialysis within 3 months; 5.Women who are lactating or pregnant; 6.Concurrent participation in other clinical trials; 7.Any other medical or psychological condition that, in the investigator’s judgment, makes the patient unsuitable for participation in this study;

Design outcomes

Primary

MeasureTime frame
Gut microbiota;Inflammation;

Countries

China

Contacts

Public ContactTian Rongrong

Hangzhou Hospital of Traditional Chinese Medicine

missingy@163.com+86 571 85827571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026